Zacks Investment Research believes Valeant Pharmaceuticals will post $2.17 billion in sales for the current financial quarter, Stock News Times reports.
Here's what you should know:
1. Five analyst firms made predictions on Valeant's quarterly sales, the lowest estimate was $2.09 billion, while the highest was $2.24 billion.
2. If the estimates are correct, it shows Valeant sales decreased 9.6 percent year over year.
3. Valeant will announce its quarterly earnings Feb. 27.
4. Analysts anticipate full-year sales between $8.65 billion to $8.80 billion.